Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Johnson & Johnson To Push Diabetes Management Model

This article was originally published in PharmAsia News

Executive Summary

At the one-year anniversary of the establishment of the Beijing Diabetes Institute (PharmAsia News, Aug. 18, 2008), Johnson & Johnson announced that it will push to improve the prevention and treatment effectiveness of diabetes and its complications. Starting with Shanghai, Zhejiang, Liaoning, Heilongjiang and Chongqing, the project will set up a highly efficient and seamless diabetes management model between hospitals and the community. Since its establishment, the Beijing diabetes institute has conducted four sessions of diabetes educator training courses in China, teaching 173 students from 25 provinces. In line with the country's healthcare reform, the institution this year began to focus on promoting its diabetes management model, which targets early detection and standardized management of the disease. (Click here for more - Chinese language)

You may also be interested in...

Johnson & Johnson Establishes Beijing Diabetes Institute

Johnson & Johnson has established its diabetes institute in Beijing, one of the company's first batch of four non-commercial institutes worldwide. The facility provides a free training platform for China's diabetes educators and managers. Over the next three years, the institute will work with the Ministry of Health to bring together local and overseas specialists and academics in the field to explore new standardized models with Chinese characteristics for managing the disease. Analysts believe the diabetes management model will allow China to maximize its health care resources to derive the most social benefits, especially previously idle community resources. (Click here for more - Chinese Language)

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts